Artelo Biosciences, Inc. Common Stock
Here’s whether Artelo Biosciences, Inc. Common Stock (ARTL) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); 50-day MA is falling (-7.45% over 10 days); RSI 4 — oversold; weak 1-year return of -93.1%; 3-month momentum negative (-69.5%); rising volume on a downtrend (distribution, 1.31x avg). Currently 98.6% off its 52-week high. Score: -7/7.
ARTL is trading below its 200-day MA ($8.82) — a key warning sign the longer-term trend is under pressure. An RSI of 3.9 has dropped into oversold territory, which has historically preceded short-term bounces. The 1-year return of -93.1% compares to +27.9% for SPY (trailed the market by 121.0%). The current 98.6% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.